Endoron Medical Ltd

Endoron Medical Ltd is an innovative medical device company focused on developing advanced solutions for patients undergoing treatment for abdominal aortic aneurysms, specifically through their proprietary technology. Founded in 2019, Endoron Medical Ltd specializes in medical devices for Endovascular Aneurysm Repair (EVAR). The company was co-founded by Eyal Teichman and Ronit Harpaz, who is also the CEO. Based in Israel, Endoron has successfully completed 2 deals as of July 2024, including a Series A funding round raising USD 10.

000 mn led by Sofinnova Partners, with participation from the European Innovation Council. Endoron Medical specializes in advanced medical devices aimed at providing solutions for patients with Abdominal Aortic Aneurysms (AAA) undergoing Endovascular Aneurysm Repair (EVAR). The company's flagship product, Aortoseal™, is a sophisticated fastening and sealing device designed to secure stent grafts in aorta repairs, mimicking the effective hand-sewn suturing technique traditionally used in open surgery. Aortoseal employs a unique stapling mechanism that allows multiple staples to penetrate both the stent graft and the aortic wall simultaneously, ensuring a secure and durable fixation that prevents graft migration and leakage.

This product is particularly beneficial for patients with complex aortic neck anatomies, which are common in 30% to 40% of AAA cases. Endoron Medical’s innovations target healthcare facilities and medical professionals in various geographical markets, including Europe and the United States, where the incidence of aortic aneurysms is significant, with approximately 2 million cases and 200,000 new diagnoses annually. Endoron Medical's revenue model primarily revolves around the sale of its Aortoseal™ device to hospitals and healthcare providers specializing in vascular surgery. The company operates on a direct-to-business transaction structure, engaging with medical facilities that perform endovascular procedures.

Each transaction typically involves bulk orders of Aortoseal units for use in surgical settings, contributing to hospital inventories. The pricing structure for Aortoseal is based on the device's technological complexity and is reflective of the value its innovative sealing mechanism provides in reducing complications and the need for reinterventions. While specific pricing details are not disclosed, Endoron Medical’s positioning in the market emphasizes the cost-effectiveness of Aortoseal in improving patient outcomes and enhancing operational efficiency for healthcare providers. In July 2024, Endoron Medical Ltd raised USD 10.

000 mn in Series A funding led by returning investor Sofinnova Partners, with participation from new investor European Innovation Council Fund. The company will use the funding to accelerate clinical validation of Endoron's EndoStapling solution Aortoseal through its Investigational Device Exemption approved Early Feasibility Study. Future plans include launching new products aimed at enhancing their existing portfolio and expanding into new markets, particularly targeting regions in Europe and the United States by the end of 2025.